Skip to content

Replimune Group REPL Return on equity

Return on equity at other companies

Amgen logo
AmgenAMGN
101.3%-4.4pp
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
14.5%-1.4pp
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
-197.8%-2,158pp
Immunome logo
ImmunomeIMNM
-50.1%-10.8pp
CG Oncology logo
CG OncologyCGON
-20.8%+7.1pp
Erasca, Inc. logo
Erasca, Inc.ERAS
-69.9%+77.1pp

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$930.59M+30.2%
Enterprise value$885.15M+30.0%

Returns & leverage

See full
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Calculated from Replimune Group’s reported figures.

Based on trailing twelve months.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Replimune Group's return on equity?
Replimune Group (REPL) reported return on equity of -90.9% in Q4 2025.
How has Replimune Group's return on equity changed year-over-year?
Replimune Group's return on equity decreased by 80.0% year-over-year, from -50.5% to -90.9%.
What is the long-term trend for Replimune Group's return on equity?
Over 4 years (2021 to 2025), Replimune Group's return on equity has grown at a 27.5% compound annual growth rate (CAGR), from -23.7% to -62.6%.
What does return on equity mean?
Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.